After being found liable for helping fuel the opioid epidemic in New York last month, Teva used the J.P. Morgan Healthcare Conference to explain how it intends to go about overturning the verdict.
The alleged overstatement of opioid volumes sold by Teva Pharmaceuticals USA Inc. in the closing remarks of the recent New York jury verdict – holding that the Israeli firm did help fuel the opioid epidemic in the state – was “not a fair way to do it,” Teva has insisted, as it revealed the latest of its plans to pursue a mistrial.
Last month, following a mammoth six-month trial, a six-member jury issued a verdict finding that Teva and certain of its...
In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.
The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.
Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
